Prasinezumab is an investigational anti-alpha-synuclein monoclonal antibody for early-stage Parkinson's disease. Roche has reported efficacy signals from Phase II programs and decided to proceed into Phase III development. Long-term open-label datasets include hundreds of participants, but the therapy is not yet approved.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07174310 |
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease |
RECRUITING | PHASE3 |
| NCT07055087 |
Prevent Cognitive Decline in GBA-associated Parkinson's Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT04777331 |
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease |
ACTIVE_NOT_RECRUITING | PHASE2 |
